2/23/2015 | CVLM | Merck gets no tenders in offer for three series of Cubist convertibles
|
1/22/2015 | CVLM | Merck tenders for three series of Cubist convertibles following merger
|
1/14/2015 | CV | Market Commentary: Morning Commentary: Tesla down outright, up on hedge; Southwestern Energy mandatory oversubscribed
|
1/13/2015 | CV | Market Commentary: Health care names better bid; Brocade extends dollar-neutral gain; Aegean Marine rises
|
12/22/2014 | PP | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
12/22/2014 | CV | Market Commentary: Gilead drops in line with shares on Express Scripts news; MGM weaker; recent deals trade
|
12/9/2014 | CV | Market Commentary: Cubist trades down after patent setback; Energy XXI drops; IGI Laboratories launches deal
|
12/9/2014 | PP | Market Commentary: Cubist trades down after patent setback; Energy XXI drops; IGI Laboratories launches deal
|
12/9/2014 | SP | New Issue: JPMorgan prices $273,000 trigger phoenix autocallables linked to Cubist Pharmaceuticals
|
12/9/2014 | CV | Market Commentary: Morning Commentary: Planned T-Mobile eyed; Envestnet, Fiat also on tap; Cubist slips
|
12/8/2014 | PP | Market Commentary: Cubist gains outright, falls on swap on Merck takeout; T-Mobile, Envestnet deals on tap
|
12/8/2014 | CV | Market Commentary: Cubist gains outright, falls on swap on Merck takeout; T-Mobile, Envestnet deals on tap
|
12/8/2014 | BKCVIG | Merck to issue $9.5 billion of debt to acquire Cubist Pharmaceuticals
|
12/8/2014 | CV | Market Commentary: Morning Commentary: Cubist jumps outright, falls on swap on Merck takeout; Cobalt down again
|
12/4/2014 | SP | JPMorgan plans trigger phoenix autocallable notes tied to Cubist
|
9/17/2014 | SP | New Issue: Deutsche Bank prices $865,000 airbag phoenix autocallables on Cubist Pharmaceuticals
|
9/11/2014 | SP | Deutsche Bank plans airbag phoenix autocallables linked to Cubist Pharmaceuticals
|
8/27/2014 | PP | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/21/2014 | PP | Market Commentary: Convertibles trade quietly, flat on hedge; Priceline unchanged; Photronics shares higher
|
8/21/2014 | CV | Market Commentary: Convertibles trade quietly, flat on hedge; Priceline unchanged; Photronics shares higher
|
8/21/2014 | CV | Market Commentary: Morning Commentary: Convertibles trade quietly; Priceline flat; Cubist active with shares higher
|
8/19/2014 | SP | New Issue: RBC prices $1.61 million 7.35% airbag autocallables linked to Cubist
|
8/12/2014 | SP | RBC plans 6%-7.5% airbag autocallable notes on Cubist Pharmaceuticals
|
7/23/2014 | PP | Market Commentary: Earnings spur activity; Xilinx drops outright, expands on hedge; Cubist adds on hedge
|
7/23/2014 | CV | Market Commentary: Earnings spur activity; Xilinx drops outright, expands on hedge; Cubist adds on hedge
|
7/23/2014 | CV | Market Commentary: Morning Commentary: Earnings in focus; Cubist in line; Xilinx convertibles down sharply
|
4/22/2014 | CV | Market Commentary: Earnings drive convertibles action; Medidata tanks outright, adds on hedge; Rambus in line
|
4/15/2014 | SP | New Issue: JPMorgan prices $2.26 million 7.5% airbag autocallables linked to Cubist
|
4/8/2014 | SP | JPMorgan to price 6%-8% airbag autocallables on Cubist Pharmaceuticals
|
12/31/2013 | CV | Outlook 2014: U.S. primary market looks stronger after 'turning a corner' in Q4; terms may cheapen
|
10/24/2013 | CV | Market Commentary: New SanDisk edges up; existing SanDisk recovers; Covanta plunges outright, adds on hedge
|
10/16/2013 | SP | New Issue: UBS prices $2.05 million 10% airbag autocallables linked to Cubist
|
10/9/2013 | SP | UBS plans 7.5%-9.5% airbag autocallables on Cubist Pharmaceuticals
|
9/25/2013 | CV | Market Commentary: Maiden mandatory prices at the mids; deal eyed as cheap ahead of terms; Rallye prices
|
9/10/2013 | CV | Cubist Pharmaceuticals greenshoes up convertible sales to $800 million
|
9/6/2013 | CV | Market Commentary: Convertibles end week on a quiet note; new Cubist issues little changed; Liberty bid 'marginally higher'
|
9/5/2013 | CV | Market Commentary: Cubist's two new tranches add on debut; Liberty exchangeable softens; Affymetrix slips
|
9/5/2013 | CV | New Issue: Cubist Pharmaceuticals prices upsized $700 million convertibles in two tranches
|
9/4/2013 | CV | Cubist's planned convertible notes upsized to $700 million; talk tightened on both tranches
|
9/4/2013 | CV | Market Commentary: New Liberty exchangeable expands on hedge; Cubist upsizes, tightens talk; Navistar slips
|
9/3/2013 | CV | Cubist plans $600 million of convertible bonds in two tranches
|
9/3/2013 | CV | Market Commentary: Convertibles mostly quiet post-break; Qihoo adds outright, on hedge; Cubist plans $600 million
|
7/31/2013 | CV | Market Commentary: Convertibles trade sideways, better amid unchanged Fed policy; NuVasive down; Meritor up
|
5/21/2013 | CV | Market Commentary: Cubist, Health Care REIT trade up in line with shares; Tesla extends drop; NetApp active
|
11/27/2012 | BK | Cubist Pharmaceuticals gets $150 million credit facility led by RBC
|
1/20/2012 | CV | Market Commentary: Convertibles turn quiet: Kinross Gold steady; Cogent quiet despite share slump; Kodak adds
|
11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
10/20/2011 | CV | Market Commentary: Cubist improves dollar neutral; Ingersoll-Rand drops; low-premium names 'better for sale'
|
10/6/2011 | CV | Market Commentary: Convertibles improve; beaten down DryShips, AMR rebound; Bank of America paper in focus
|
9/30/2011 | CV | Market Commentary: Convertibles sell off; GMX, MGM trade lower; Kodak drops sharply on restructuring fears
|
9/9/2011 | CV | Market Commentary: Convertibles under pressure as equities drop; Amerigroup, RadioShack lower; Dendreon flat
|
8/30/2011 | CV | Market Commentary: Kodak improves dollar neutral after CEO comments; Cubist paper adds; Radian extends gains
|
7/11/2011 | CV | Market Commentary: Convertibles sink with drop in equities; Virgin Media, Coinstar slip; Alcoa earnings eyed
|
6/29/2011 | CV | Market Commentary: Liquid names in trade; U.S. Steel lags underlying shares; Cameron trades ahead of call
|
5/27/2011 | CV | Market Commentary: Salesforce ends week slightly better; MannKind trades as shares creep up; Cubist mixed
|
5/26/2011 | CV | Market Commentary: Akorn trades up on debut; NetApp gains outright after raised guidance; Cubist in action
|
5/24/2011 | CV | Market Commentary: Cubist flat to lower amid takeover chatter; Medtronic 'for sale' after disappointing earnings
|
4/5/2011 | CV | Market Commentary: Cubist mixed dollar neutral after Teva agreement; Ciena mixed; Horizon Lines recoups some
|
12/3/2010 | CV | Market Commentary: Clearwire slumps on debut as hedge players steer clear; Vertex below par; Cameron rises
|
10/25/2010 | CV | Cubist Pharmaceuticals $50 million greenshoe exercised in full
|
10/22/2010 | CV | Market Commentary: SanDisk higher after earnings; ViroPharma up 0.5 point on swap; new Cubist moves above par
|
10/21/2010 | CV | Market Commentary: Cubist, Amylin in focus, unchanged in trade; Alliance Data, Covanta steady after earnings
|
10/20/2010 | CV | Market Commentary: New Cubist trades slightly over par; Amylin gets slammed but pares losses; Gilead quiet
|
10/19/2010 | CV | New Issue: Cubist prices upsized $400 million seven-year convertibles to yield 2.5%, up 25%
|
10/19/2010 | CV | Market Commentary: Cubist's upsized $400 million convertibles price, seen 1% cheap before pricing; EMC mixed
|
10/18/2010 | CV | Cubist to price $250 million seven-year convertibles to yield 2.25%-2.75%, up 22.5%-27.5%
|
10/18/2010 | CV | Market Commentary: NII Holdings flat to lower on scuttled wireless agreement; EMC mixed; Cubist deal on tap
|
8/7/2009 | CV | Market Commentary: Onyx, Rayonier price rich, jump; D.R. Horton up with sector; Cubist gets pre-conference boost
|
7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
2/10/2009 | CV | Market Commentary: Financials lower after bank plan; other convertibles hold up as equities slide; AMD steady
|
1/23/2009 | CV | Market Commentary: Convertibles bounce around; selling hits Nabors, Transocean, AMD; Cubist up on earnings; Wyeth up
|
2/7/2008 | CV | Cubist buys back $50 million of 2.25% convertibles
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/16/2006 | BT | Cubist looking for in-licensing opportunities to fill 'gap in pipeline'
|
10/19/2006 | BT | JMP keeps Cubist at strong buy
|
10/19/2006 | BT | RBC reiterates Cubist at outperform
|
10/19/2006 | BT | Cubist still at buy by Merrill
|
10/18/2006 | BT | Cubist report first profitable quarter; cash up at $282 million
|
10/10/2006 | BT | RBC keeps Cubist at outperform
|
10/2/2006 | BT | Cubist at buy by Merrill
|
9/5/2006 | BT | Cubist reiterated at outperform by RBC
|
8/23/2006 | BT | Cubist reiterated at strong buy by JMP
|
8/23/2006 | BT | Market Commentary: Cell Therapeutics' stock takes off on positive phase 1 data; Cubist's stock up again on Theravance news
|
8/23/2006 | BT | Merrill reiterates Cubist at buy
|
8/22/2006 | BT | Market Commentary: Protalix gets $15 million investment as part of merger; Theravance sees positive telavancin trial results
|
8/17/2006 | BT | Cubist reiterated at outperform by RBC
|
8/8/2006 | BT | Cubist reiterated at strong buy by JMP
|
7/28/2006 | BT | XOMA suspends HepeX-B, terminates contract with Cubist
|
7/24/2006 | BT | Cubist reiterated at buy by Merrill
|
7/20/2006 | BT | JMP reiterates Cubist at strong buy
|
7/20/2006 | BT | Cubist maintained at buy by Merrill
|
7/20/2006 | BT | Cubist at outperform by RBC
|
7/20/2006 | BT | XTL says Cubist's decision to put HepeX-B on hold has little impact
|
7/19/2006 | BT | Cubist reports $5.1 million net loss for second quarter
|
7/5/2006 | BT | Merrill Lynch predicting solid second-quarter earnings, Cubist best bet for upside
|
6/30/2006 | BT | RBC puts Cubist at outperform
|
6/29/2006 | CV | Market Commentary: Red Hat rises dollar-neutral, falls outright; new Vector bid higher; CNET, Intel gain; Nexans prices deal
|
6/26/2006 | BT | Cubist reiterated at buy by Merrill
|
6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
6/12/2006 | BT | Cubist says label expansion distinguishes Cubicin in infectious disease market
|
6/8/2006 | BTCV | Cubist Pharmaceuticals to redeem 5.5% convertibles due 2008
|
6/5/2006 | BTCV | Cubist Pharmaceuticals greenshoe exercised, raising convertibles issue to $350 million
|
6/2/2006 | CV | Market Commentary: Trinity gains on debut; Novell improves further on volatility, takeover speculation; Encysive gains outright
|
6/1/2006 | BTCV | New Issue: Cubist prices upsized $325 million seven-year convertibles at 2.25%, up 30%
|
6/1/2006 | BT | Market Commentary: Targeted Genetics' stock jumps 18% on promising data; Endologix raises $20.13 million from stock sale
|
6/1/2006 | CV | Market Commentary: Cubist stacks up well on debut; Novell holds up against weak guidance; Trinity gains in the gray
|
5/31/2006 | BT | Market Commentary: Gentium gains on PIPE; Cubist holders await convertible smoke to clear; Crucell up; Durect higher
|
5/31/2006 | CV | Market Commentary: Cubist climbs in gray market; L-3 improves on stock downgrade; Novell seen to firm on poor guidance
|
5/31/2006 | BTCV | Cubist prices upsized $325 million of convertibles at 2.25%, up 30%
|
5/31/2006 | BT | RBC raises estimates for Cubist
|
5/30/2006 | BT | Market Commentary: Cubist new convertible emerges; Vical zooms; Isis climbs; ISTA off despite news; CollaGenex climbs
|
5/30/2006 | CV | Market Commentary: CA up dollar-neutral amid delayed earnings; Level 3 deal seen as attractive; Cubist plans deal as expected
|
5/30/2006 | BTCV | Cubist to price $275 million of 7-year convertibles, talked at 2.25%-2.75%, up 25%-30%
|
5/26/2006 | BT | Market Commentary: Anadys spikes on thin volume; Cubist extends gain on Cubicin nod; Tanox, Momenta, Epix up
|
5/26/2006 | CV | Market Commentary: Credence firm despite downgrades; Cubist gains on FDA approval; Nabors, Transocean up with stocks
|
5/26/2006 | BT | Rodman & Renshaw starts Cubist at market outperform
|
5/26/2006 | BT | RBC rates Cubist at outperform
|
5/26/2006 | BT | Cubist reiterated at buy by Merrill
|
5/26/2006 | BT | JMP keeps Cubist at strong buy
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/25/2006 | BT | Cubist gets FDA approval of expanded label for Cubicin
|
5/25/2006 | BT | Cubist kept at buy rating by Merrill
|
5/23/2006 | BT | RBC rates Cubist at outperform
|
5/18/2006 | BT | RBC quarterly biotechnology update
|
4/20/2006 | BT | Market Commentary: MedImmune dives 12%; Cubist gains over 9%; Discovery Labs, Dynavax rise on financing deals
|
4/20/2006 | BT | Cubist reiterated at strong buy by JMP
|
4/20/2006 | BT | Merrill reiterates Cubist at buy
|
3/27/2006 | BT | JMP reiterates Cubist at strong buy
|
3/27/2006 | BT | Merrill maintains Cubist at buy
|
3/27/2006 | BT | Market Commentary: Amylin drops 3% on follow-on; Keryx up 3% on PIPE; Cubist off; Cephalon off, Generex dives 20%
|
3/27/2006 | BT | Cubist Pharmaceuticals responds to FDA approvable letter
|
3/24/2006 | BT | Cubist announces FDA approvable letter for Cubicin sNDA
|
3/20/2006 | BT | Merrill reiterates Cubist at buy
|
3/7/2006 | BT | Merrill reiterates Cubist at buy, raises target
|
3/7/2006 | BT | JMP puts Cubist at strong buy
|
3/7/2006 | BT | Market Commentary: Advanced Magnetics raises $32 million; Genta pockets $41 million; Favrille bags $45 million; Cubist rises 4%
|
3/6/2006 | BT | Cubist's Cubicin backed by FDA committee to treat S. aureus bacteremia, infective endocarditis
|
3/6/2006 | BT | Market Commentary: Cubist players hedging bets with puts; Insmed follow-on emerges; Elan up; Titan zooms; LifeCell up
|
2/28/2006 | BT | Merrill reiterates Cubist at buy
|
1/24/2006 | BT | Merrill reiterates Cubist at buy
|
1/24/2006 | BT | Cubist kept at strong buy by JMP
|
1/23/2006 | BT | FDA's review of Cubist's sNDA for Cubicin set for March
|
1/23/2006 | BT | Cubist maintained at buy by Merrill
|
1/23/2006 | BT | Cubicin granted marketing approval in Europe
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/9/2006 | BT | Cubist reiterated by Merrill at buy
|
12/21/2005 | BT | Cubist: phase 2 data shows HepeX-B staves off re-infection by virus in liver transplant patients
|
12/19/2005 | BT | JMP reiterates Cubist at strong buy
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/19/2005 | BT | Cubist reiterated by Merrill at buy
|
12/16/2005 | BT | Cubist's Cubicin matches current standard of care for serious bacterial infections, study says
|
12/9/2005 | BT | Cubist reiterated by Merrill at buy
|
12/8/2005 | BT | Cubist says new study shows Cubicin effective therapy for staphylococcus aureus bacteremia
|
11/23/2005 | BT | JMP reiterates Cubist at strong buy
|
11/22/2005 | BT | Cubist still buy, Merrill Lynch says
|
11/21/2005 | BT | Cubist's Supplemental New Drug Application for Cubicin antibiotic granted FDA priority review
|
11/21/2005 | BT | Cubist buy rating reiterated by Merrill Lynch
|
11/18/2005 | BT | Merrill reiterates Cubist buy
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/7/2005 | BT | Merrill Lynch reiterates Cubist at buy
|
10/20/2005 | BT | JMP reiterates Cubist at strong buy, raises price target
|
10/20/2005 | BT | Merrill Lynch maintains Cubist at buy
|
10/13/2005 | BT | Cubist buy rating reiterated by Merrill
|
10/4/2005 | BT | Cubist maintained by Merrill Lynch at buy
|
9/26/2005 | BT | Cubist price target upped by Merrill Lynch
|
9/23/2005 | BT | Market Commentary: Nektar upsizes home-run convertible, Renovis raves, Acusphere sinks after follow-ons; Cyberonics slips
|
9/23/2005 | BT | Cubist reiterated by Merrill Lynch at buy
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/14/2005 | BT | Cubist kept by Thomas Weisel at outperform
|
9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
8/15/2005 | BT | Biotechnology's solid second quarter a harbinger, Anadys one to watch, JMP Securities report says
|
8/10/2005 | BT | Cubist maintained by Merrill Lynch at buy
|
7/21/2005 | BT | Cubist estimates raised by Merrill
|
7/18/2005 | BT | Cubist reiterated by Merrill Lynch at buy
|
7/14/2005 | BT | Cubist initiated by Merrill at buy
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
6/28/2005 | BT | Market Commentary: Lonza, CV Therapeutics converts on tap; Cubist zooms; Abgenix up on belt tightening; Wyeth a boost
|
6/16/2005 | BT | Market Commentary: Pfizer purchase spurs speculative buying; Cubist advances; ev3, Micrus, Gentium IPOs discounted
|
5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
12/14/2004 | PP | Cubist Pharmaceuticals repays 81/2% senior convertible notes
|
7/5/2002 | CV | Market Commentary: Convertibles marked higher in very thin post-holiday session
|
12/24/2001 | CV | Cubist Pharmaceuticals says greenshoe exercised, raising convertibles to $165 million
|
10/24/2001 | CV | Market Commentary: Convertible market higher as $1 bln in new deals emerge
|
10/23/2001 | CV | New Issue: Cubist Pharma $125 mln convertibles at 5.5% yield, up 10%
|
10/23/2001 | CV | Market Commentary: Convertible market flat to higher as stocks dip
|
10/22/2001 | CV | Cubist Pharma $125 mln converts talked at 5.0%-5.25% yield, 10%-15%% premium
|
10/22/2001 | CV | Market Commentary: Convertibles gain with stocks, new deals keep coming
|